Kibow Biotech, Inc.
Profile
https://www.dropbox.com/s/i5v3htuvgm8he6u/Kibow%20ASN2016%20Promotional%20Flyer.pdf?dl=0
As per the KidneyX program, there has been little to no innovation in the treatment of kidney disease other than HD/ PD. Now known as the “Gut-Kidney connection,” Kibow Biotech’s “ENTERIC DIALYSIS®” a concept conceived in 1997. It is based on modulating and stabilizing the “Gut Microbiome” with a patented proprietary formulation of probiotics and prebiotics. Kibow’s Renadyl™ is patented, clinically validated formulations that promote healthy kidney function. Clinical data shows that Renadyl™ helps stabilize kidney function (eGFR) by metabolizing several uremic toxins that diffuse from circulating blood into the bowel as a consequence of CKD and dysbiosis. In combination with standard of care therapy, Renadyl™ shows the potential to improve patient outcomes tremendously and as well help slow the progression of CKD with greatly improved quality of life. Systematic review and meta-analysis demonstrated potential beneficial effects of probiotics on inflammation, & uremic toxins and GI symptoms in CKD Patients. It is now seen as a Live Biotherapeutic Product (LBP) by the US FDA, and as such Kibow is exploring this technology used in Renadyl as a possible Rx product.